Nasopharyngeal Cancer (Oncology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngeal Cancer – Drugs In Development, 2021, provides an overview of the Nasopharyngeal Cancer (Oncology) pipeline landscape.

Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking, including hoarseness, ear infections that keep coming back, face pain or numbness, headache, hearing loss, ringing in the ears. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasopharyngeal Cancer – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 6, 27, 28, 1, 18, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 5, 9 and 1 molecules, respectively.

Nasopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer (Oncology).

– The pipeline guide reviews pipeline therapeutics for Nasopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Nasopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Nasopharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Nasopharyngeal Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Nasopharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

ADC Therapeutics SA

Advenchen Laboratories LLC

Akeso Inc

Alphamab Oncology

Ambrx Biopharma Inc

Apollomics Inc

Argenx SE

Ascentage Pharma Group International

AstraZeneca Plc

Atara Biotherapeutics Inc

AVEO Pharmaceuticals Inc

BeiGene Ltd

Biomics Biotechnologies Co Ltd

BioSyngen Pte Ltd

BP InnoMed Ltd

Bristol-Myers Squibb Co

Chengdu Wonho Biology Engineering Co Ltd

China Immunotech Co Ltd

CytoMed Therapeutics Pte Ltd

Eli Lilly and Co

Eutilex Co Ltd

Exelixis Inc

F. Hoffmann-La Roche Ltd

Geneius Biotechnology Inc

GenFleet Therapeutics (Shanghai) Inc

Genrix (Shanghai) Biopharmaceutical Co Ltd

Guangzhou Bairui Biomedical Technology Co Ltd

Guangzhou Doublle Bioproduct Inc

Guangzhou Hanghua Bio Pharmaceutical Technology Co

Harbin Gloria Pharmaceuticals Co Ltd

Huabo Biopharm (Shanghai) Co Ltd

Immunomic Therapeutics Inc

Incyte Corp

Inhibrx Inc

Innovent Biologics Inc

Jiangsu Hengrui Medicine Co Ltd

Joint Biosciences Ltd

Kuur Therapeutics Ltd

Lion TCR Pte Ltd

Merck KGaA

Nanjing Iaso Biotherapeutics Co Ltd

Neonc Technologies Inc

Novartis AG

Noxopharm Ltd

Ono Pharmaceutical Co Ltd

Oxford Vacmedix UK Ltd

PNP Therapeutics Inc

Polaris Pharmaceuticals Inc

RAPT Therapeutics Inc

Seven and Eight Biopharmaceuticals Corp

Shanghai GeneChem Co Ltd

Shanghai Junshi Bioscience Co Ltd

Shanghai Miracogen Inc

Sichuan Kelun Pharmaceutical Co Ltd

Soricimed Biopharma Inc

Suzhou Zelgen Biopharmaceutical Co Ltd

TCR Cure Biopharma Technology Co Ltd

Tessa Therapeutics Ltd

Vectorite Biomedical Inc

Viracta Therapeutics Inc

Xencor Inc

Xiangxue Life Sciences

Table of Contents

Table of Contents

Introduction

Nasopharyngeal Cancer - Overview

Nasopharyngeal Cancer - Therapeutics Development

Nasopharyngeal Cancer - Therapeutics Assessment

Nasopharyngeal Cancer - Companies Involved in Therapeutics Development

Nasopharyngeal Cancer - Drug Profiles

Nasopharyngeal Cancer - Dormant Projects

Nasopharyngeal Cancer - Discontinued Products

Nasopharyngeal Cancer - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Nasopharyngeal Cancer, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Nasopharyngeal Cancer – Pipeline by ADC Therapeutics SA, 2021

Nasopharyngeal Cancer – Pipeline by Advenchen Laboratories LLC, 2021

Nasopharyngeal Cancer – Pipeline by Akeso Inc, 2021

Nasopharyngeal Cancer – Pipeline by Alphamab Oncology, 2021

Nasopharyngeal Cancer – Pipeline by Ambrx Biopharma Inc, 2021

Nasopharyngeal Cancer – Pipeline by Apollomics Inc, 2021

Nasopharyngeal Cancer – Pipeline by Argenx SE, 2021

Nasopharyngeal Cancer – Pipeline by Ascentage Pharma Group International, 2021

Nasopharyngeal Cancer – Pipeline by AstraZeneca Plc, 2021

Nasopharyngeal Cancer – Pipeline by Atara Biotherapeutics Inc, 2021

Nasopharyngeal Cancer – Pipeline by AVEO Pharmaceuticals Inc, 2021

Nasopharyngeal Cancer – Pipeline by BeiGene Ltd, 2021

Nasopharyngeal Cancer – Pipeline by Biomics Biotechnologies Co Ltd, 2021

Nasopharyngeal Cancer – Pipeline by BioSyngen Pte Ltd, 2021

Nasopharyngeal Cancer – Pipeline by BP InnoMed Ltd, 2021

Nasopharyngeal Cancer – Pipeline by Bristol-Myers Squibb Co, 2021

Nasopharyngeal Cancer – Pipeline by Chengdu Wonho Biology Engineering Co Ltd, 2021

Nasopharyngeal Cancer – Pipeline by China Immunotech Co Ltd, 2021

Nasopharyngeal Cancer – Pipeline by CytoMed Therapeutics Pte Ltd, 2021

Nasopharyngeal Cancer – Pipeline by Eli Lilly and Co, 2021

Nasopharyngeal Cancer – Pipeline by Eutilex Co Ltd, 2021

Nasopharyngeal Cancer – Pipeline by Exelixis Inc, 2021

Nasopharyngeal Cancer – Pipeline by F. Hoffmann-La Roche Ltd, 2021

Nasopharyngeal Cancer – Pipeline by Geneius Biotechnology Inc, 2021

Nasopharyngeal Cancer – Pipeline by GenFleet Therapeutics (Shanghai) Inc, 2021

Nasopharyngeal Cancer – Pipeline by Genrix (Shanghai) Biopharmaceutical Co Ltd, 2021

Nasopharyngeal Cancer – Pipeline by Guangzhou Bairui Biomedical Technology Co Ltd, 2021

Nasopharyngeal Cancer – Pipeline by Guangzhou Doublle Bioproduct Inc, 2021

Nasopharyngeal Cancer – Pipeline by Guangzhou Hanghua Bio Pharmaceutical Technology Co, 2021

Nasopharyngeal Cancer – Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2021

Nasopharyngeal Cancer – Pipeline by Huabo Biopharm (Shanghai) Co Ltd, 2021

Nasopharyngeal Cancer – Pipeline by Immunomic Therapeutics Inc, 2021

Nasopharyngeal Cancer – Pipeline by Incyte Corp, 2021

Nasopharyngeal Cancer – Pipeline by Inhibrx Inc, 2021

Nasopharyngeal Cancer – Pipeline by Innovent Biologics Inc, 2021

Nasopharyngeal Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021

Nasopharyngeal Cancer – Pipeline by Joint Biosciences Ltd, 2021

Nasopharyngeal Cancer – Pipeline by Kuur Therapeutics Ltd, 2021

Nasopharyngeal Cancer – Pipeline by Lion TCR Pte Ltd, 2021

Nasopharyngeal Cancer – Pipeline by Merck KGaA, 2021

Nasopharyngeal Cancer – Pipeline by Nanjing Iaso Biotherapeutics Co Ltd, 2021

Nasopharyngeal Cancer – Pipeline by Neonc Technologies Inc, 2021

Nasopharyngeal Cancer – Pipeline by Novartis AG, 2021

Nasopharyngeal Cancer – Pipeline by Noxopharm Ltd, 2021

Nasopharyngeal Cancer – Pipeline by Ono Pharmaceutical Co Ltd, 2021

Nasopharyngeal Cancer – Pipeline by Oxford Vacmedix UK Ltd, 2021

Nasopharyngeal Cancer – Pipeline by PNP Therapeutics Inc, 2021

Nasopharyngeal Cancer – Pipeline by Polaris Pharmaceuticals Inc, 2021

Nasopharyngeal Cancer – Dormant Projects, 2021

Nasopharyngeal Cancer – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Nasopharyngeal Cancer, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports